August 20, 2024 — Semaglutide – under the banner of Ozempic – has set a revolution of obesity medicines in motion. Suddenly, all of the huffing and puffing about “treating obesity seriously” and “obesity as a disease” is moot. Facts on the ground are persuading people to re-orient their thinking about obesity faster than essays and advocacy campaigns ever […]
October 3, 2023 — It’s enough to make our heads spin. The incredible vibrancy in obesity research is on full display at the meeting of the European Association for the Study of Diabetes – EASD 2023 in Hamburg. Today, it starts with a bang. Successive presentations on multi-agonists for obesity are scheduled this afternoon at EASD. But the abstracts […]
June 27, 2023 — The last of four big days at ADA2023 brought us astonishing results from three studies of a new obesity medicine, retatrutide. This is the first 3-in-1 metabolic receptor agonist to advance this far in clinical trials as a medicine for obesity or diabetes. Researchers presented phase 2 results for obesity, diabetes, and NAFLD – three […]
